Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 2:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Drug Evaluation Clear all

Completed Phase 2 Interventional

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.

NCT00398645

View directory record Official record

Conditions: Asthma
Interventions: GW685698X 200mcg,GW685698X 200mcg and 400mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older

Enrollment: 648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 16
States / cities: Fullerton, California • Huntington Beach, California • Orange, California + 13 more

Source: ClinicalTrials.gov public record

Updated Jan 22, 2018 · Synced May 22, 2026, 2:47 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects

NCT01757860

View directory record Official record

Conditions: Drug Safety, Heart; Disease, Activity
Interventions: CARD-024, Drug Carrier; Drug · Other
Lead sponsor: Cardiavent Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Source: ClinicalTrials.gov public record

Updated Dec 30, 2012 · Synced May 22, 2026, 2:47 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

NCT05347979

View directory record Official record

Conditions: Cushing Syndrome, Neoplasms
Interventions: Dabigatran Etexilate, Relacorilant; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Source: ClinicalTrials.gov public record

Updated Feb 8, 2023 · Synced May 22, 2026, 2:47 AM EDT

Completed Phase 3 Interventional Accepts healthy volunteers

Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers

NCT00223951

View directory record Official record

Conditions: Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis
Interventions: R89674 (generic name not yet established); Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 3 Years and older

Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 6
States / cities: Phoenix, Arizona • Bel Air, Maryland • North Andover, Massachusetts + 3 more

Source: ClinicalTrials.gov public record

Updated Feb 19, 2015 · Synced May 22, 2026, 2:47 AM EDT

Active, not recruiting Phase 2 Interventional

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

NCT01217931

View directory record Official record

Conditions: Kidney Cancer
Interventions: Pazopanib, Bevacizumab, Everolimus; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Jan 29, 2026 · Synced May 22, 2026, 2:47 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Multiple Doses of Isavuconazole and a Single Dose of Bupropion

NCT01635972

View directory record Official record

Conditions: Pharmacokinetics of Isavuconazole, Pharmacokinetics of Bupropion, Healthy Volunteers
Interventions: Isavuconazole, bupropion hydrochloride; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Source: ClinicalTrials.gov public record

Updated Aug 31, 2015 · Synced May 22, 2026, 2:47 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

NCT05852769

View directory record Official record

Conditions: Healthy Volunteers
Interventions: BMS-986196, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, Pravastatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Millcreek, Utah

Source: ClinicalTrials.gov public record

Updated Sep 25, 2023 · Synced May 22, 2026, 2:47 AM EDT

Completed Phase 1 Interventional Results available

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

NCT01770353

View directory record Official record

Conditions: Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
Interventions: Ferumoxytol, MM-398; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older

Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 7
States / cities: Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more

Source: ClinicalTrials.gov public record

Updated Nov 26, 2019 · Synced May 22, 2026, 2:47 AM EDT

Completed Phase 1 Interventional Results available

A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer

NCT00927589

View directory record Official record

Conditions: Solid Cancers
Interventions: carboplatin, docetaxel, trastuzumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 20
States / cities: Scottsdale, Arizona • Beverly Hills, California • La Jolla, California + 16 more

Source: ClinicalTrials.gov public record

Updated Dec 9, 2015 · Synced May 22, 2026, 2:47 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

NCT05109390

View directory record Official record

Conditions: Healthy
Interventions: Danicopan, Cyclosporine, Tacrolimus, Calcium Carbonate, Aluminum/Magnesium Hydroxide/Simethicone, Omeprazole; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Source: ClinicalTrials.gov public record

Updated Nov 4, 2021 · Synced May 22, 2026, 2:47 AM EDT

Not yet recruiting Phase 4 Interventional

Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1

NCT07554417

View directory record Official record

Conditions: GLP - 1, Obesity & Overweight, Muscle Loss, Exercise Intervention, Dietary Assessment
Interventions: Semaglutide, Dietary Counseling, Exercise; Drug · Behavioral
Lead sponsor: William Marsh Rice University; Other
Eligibility: 40 Years to 55 Years

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Apr 27, 2026 · Synced May 22, 2026, 2:47 AM EDT

Completed Phase 3 Interventional Results available

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

NCT01137474

View directory record Official record

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Placebo-matching dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 89 Years

Enrollment: 2,996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 164
States / cities: Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 124 more

Source: ClinicalTrials.gov public record

Updated Jan 25, 2017 · Synced May 22, 2026, 2:47 AM EDT

Withdrawn Not applicable Interventional Accepts healthy volunteers

An Investigation of a Multi-Function Skincare Product to Improve Aging, Eczema, and Acne Outcomes

NCT05873933

View directory record Official record

Conditions: Acne, Eczema, Skin Aging
Interventions: Hemptress Oil; Other
Lead sponsor: Hemptress; Industry
Eligibility: 21 Years to 65 Years

Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Santa Monica, California

Source: ClinicalTrials.gov public record

Updated Oct 8, 2024 · Synced May 22, 2026, 2:47 AM EDT

Completed Phase 1 Interventional Results available

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

NCT02122770

View directory record Official record

Conditions: Advanced Solid Tumors
Interventions: MLN4924, Fluconazole, Itraconazole, Docetaxel, Carboplatin, Paclitaxel; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: Atlanta, Georgia • St Louis, Missouri • Nashville, Tennessee + 1 more

Source: ClinicalTrials.gov public record

Updated Jan 6, 2019 · Synced May 22, 2026, 2:47 AM EDT

Completed Not applicable Interventional

Evaluation and Treatment of Oral Soft Tissue Diseases

NCT00001601

View directory record Official record

Conditions: Aphthous Stomatitis, Burning Mouth Syndrome, Lichen Planus, Mouth Disease, Temporomandibular Joint Disorder
Interventions: Electrocardiogram, Biopsies, Diagnostic imaging; Procedure
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed

Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Mar 3, 2008 · Synced May 22, 2026, 2:47 AM EDT

Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

NCT02689206

View directory record Official record

Conditions: Anaemia
Interventions: GSK1278863, GSK1278863 matching Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older

Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Northridge, California • San Dimas, California • Pembroke Pines, Florida + 4 more

Source: ClinicalTrials.gov public record

Updated Feb 24, 2020 · Synced May 22, 2026, 2:47 AM EDT

Completed Not applicable Interventional Accepts healthy volunteers Results available

Mechanisms of Action of Acetaminophen

NCT00646906

View directory record Official record

Conditions: Myocardial Infarction, Arthritis
Interventions: Aspirin First, Aspirin Last, Acetaminophen 1000 mg/d, Acetaminophen 4000 mg/d, Ibuprofen 800 mg/d; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 55 Years

Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Feb 11, 2026 · Synced May 22, 2026, 2:47 AM EDT

Completed Phase 2 Interventional

The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection

NCT00002347

View directory record Official record

Conditions: HIV Infections
Interventions: Saquinavir, Nevirapine, Zidovudine, Zalcitabine; Drug
Lead sponsor: Parexel; Industry
Eligibility: 13 Years and older

Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Waltham, Massachusetts

Source: ClinicalTrials.gov public record

Updated Jun 23, 2005 · Synced May 22, 2026, 2:47 AM EDT

Completed Phase 3 Interventional Results available

A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

NCT00531817

View directory record Official record

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab, Placebo, Permitted DMARDs; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older

Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 156
States / cities: Birmingham, Alabama • Montgomery, Alabama • Lake Havasu City, Arizona + 135 more

Source: ClinicalTrials.gov public record

Updated Aug 19, 2012 · Synced May 22, 2026, 2:47 AM EDT

Terminated Phase 3 Interventional

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

NCT01969123

View directory record Official record

Conditions: Alzheimer's Disease, Dementia
Interventions: Drug: EVP-6124, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 55 Years to 85 Years

Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 44
States / cities: Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 41 more

Source: ClinicalTrials.gov public record

Updated May 2, 2016 · Synced May 22, 2026, 2:47 AM EDT

Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

NCT03358706

View directory record Official record

Conditions: Crohn Disease, Ulcerative Colitis
Interventions: Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Cypress, California • Miami Springs, Florida • Durham, North Carolina

Source: ClinicalTrials.gov public record

Updated Aug 20, 2025 · Synced May 22, 2026, 2:47 AM EDT

Terminated Phase 2 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

NCT04888585

View directory record Official record

Conditions: Rheumatoid Arthritis (RA)
Interventions: ABBV-154, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 101
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more

Source: ClinicalTrials.gov public record

Updated Oct 7, 2024 · Synced May 22, 2026, 2:47 AM EDT

Completed Not applicable Interventional

An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection

NCT00000647

View directory record Official record

Conditions: HIV Infections
Interventions: CD4-IgG, Zidovudine, Interferon alfa-n1, Peripheral lymphocyte infusion, Bone marrow transplant; Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years

Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Oct 26, 2021 · Synced May 22, 2026, 2:47 AM EDT

Completed No phase listed Observational

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

NCT00458887

View directory record Official record

Conditions: Ototoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: management of therapy complications; Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 18 Years

Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 73
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 65 more

Source: ClinicalTrials.gov public record

Updated Mar 12, 2017 · Synced May 22, 2026, 2:47 AM EDT